The announcement of a cancer diagnosis is a tsunami that stops a life in its tracks, leaving indelible scars and even shattering it completely. Treatment offers repair and reconstruction, healing the body and restoring its integrity. Treatment through remission and healing gives a second chance at life, which takes on an enhanced, unprecedented and new value that every patient feels after being so afraid of losing it.
The ABCELY logo was inspired by the Japanese tradition of ceramic repair, which, instead of hiding fractures and scars, sublimates them by highlighting them in gold, creating a work of art of immense value while restoring its original functionality. Life is never the same after such an experience, both in body and soul. With humility, our logo seeks to symbolize a life rebuilt and sublimated after such a devastating illness.
Innovation for the oral treatment of mucosal cancers
Develop a safe and efficient therapeutic platform based on oral monoclonal IgA antibodies
Global incidence: new cases/year 5 years survival rate (Source IARC 2020)
IgA is a unique antibody suitable for Oral immunotherapy
as an alternative to exclusively IV/SC IgG administration
IgA is extremely difficult to sort from standard hybridoma techniques (1% IgA vs 40% IgM, 60% IgG) and has thus being up to now under estimated by Pharma at the benefit of IgG approaches.
Abcely has developped a unique platform for the Identification, Lead Optimisation, Manufacturing, Analysis and in vitro/vivo testing of slgA
Secretory IgA (sIgA) is extremely resistant to enzymatic attacks and high pH variations (from acidic to basic)
Secretory IgA is actively absorbed without degradation by receptors expressed on M cells, mostly located in Peyer Patches in human ileum
Carcinoembryonic antigen (CEA), present at the apical membrane of cells in normal tissues, is one of the most widely used tumor marker for monitoring tumor recurrence after surgical resection and prognosis.
CEA overexpression is associated to many types of cancers (up to 98% of colorectal cancers)
IgA is the only relevant Ig to target CEA because IgG binds to the plasma CEA and does not reach the tumor efficiently
In vivo efficacy of ABC-101 in an advanced metastatic CRC model
After 3 weeks of oral treatment, ABC-101 was well tolerated
As a first-line monotherapy, ABC-101 signicantly reduced tumor size when given orally and showed a higher therapeutic benefit than the clinical IgG SOC (Erbitux®) given in IV
In combination with Irinotecan, ABC-101 given orally showed a stronger therapeutic benefit on tumor growth than the IV Gold standard IgG, Erbitux®
In vivo efficacy
of ABC-101 in
an advanced
metastatic CRC
Development plan – Key steps
Leadership Team
Our partners
Scientific Advisory Board
Pr. S. Paul, PhD
CHU, Saint-Etienne, FR
Professor / Practitioner
Immunology & Vaccinology
Pr. M. Van Egmond, PhD
UMC, Amsterdam, NL
Professor in Oncology and inflammation
Pr. M. Ducreux, MD
IGR, Paris FR
Former chair of the EORTC
Co-Chair of the ESMO Gastrointestinal cancers Congress 2024
Strategic Board
Leila Nicolas, PhD
Partner at Go Capital
Gabriel Festoc
Former CEO at Polyplus
Stéphane Loze, PhD
Former head of strategy and oncology therapeutic units at Roche
Marc Bonneville, PhD
Co-founder of Innate Pharma
BuroClub • Immeuble l’Acropole • 2, rue Crucy 44000 Nantes • France